This article will be of immense benefit to all of us involved in mortality and morbidity meetings and Clinical Governance, especially registrars and junior members of the team. The authors present data from the UK, USA and Europe. In prostate...
The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...
Orchid was established in 1996 by a young testicular cancer patient, Colin Osborne MBE, and the oncologist who saved his life, Professor Tim Oliver MD, FRCP. The charity exists to save men’s lives from testicular, penile, and prostate cancers and...
The authors evaluated the pathological and oncological characteristics of anteriorly located prostate cancer (APC) in 728 RP specimens, and the accuracy of multiparametric magnetic resonance imaging (MP-MRI) for APC evaluation. Patients were characterised as APC (70% or more of tumour...
Countless epidemiological studies have established the frequent occurrence of lower urinary tract symptoms (LUTS) and the significant burden these symptoms incur. For the most part of the past three decades, there has been an overwhelming focus on detrusor overactivity (DO)...
Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...
Prostate Cancer UK recently reported that there is an impending crisis for men with prostate cancer, simply because the number of nurse specialists available is insufficient for their needs [1]. Background As has been widely reported, the incidence of prostate...
For 2019, Sweden’s second city, Gothenburg, welcomes the Annual Scientific Meeting of the International Continence Society. Not since 1981, when Lund was the host, has Sweden hosted the ICS and the local organising committee are working hard to ensure that...
From the first cystoscopic argon and neodymium-YAG (yttrium-aluminium-garnet) laser used for bladder tumours in 1976 by Staehler et al. [1], lasers have proven to be a versatile and an evolving tool in the therapeutic management of a variety of urological...
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...